Lisa Anne Bero, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lisa Anne Bero, PhD

Professor, Department of Clinical Pharmacy and Institute for Health Policy Studies, UCSF

bero@medicine.ucsf.edu

Phone: (415) 476-1067 (voice)
Box 0613, UCSF

View on UCSF Profiles

Cancer Center Membership

Program Member » Tobacco Control

Education

Michigan State University, East Lansing, MI, B.S. (honors), 1980, Physiology/Philosophy
Duke University, Durham, NC, Ph.D., 1987, Pharmacology
NIDA Postdoctoral Fellowship, University of California, San Francisco (UCSF), 1987-88, Pharmacology
Pew Health Policy Fellowship, UCSF, 1988-90, Health Policy
1987-1988 NIDA Postdoctoral Fellow, University of California, San Francisco, CA (UCSF)


Professional Experience

  • 1988-1992
    Pew Fellowship, Institute for Health Policy Studies, UCSF
  • 1994-present
    Co-Director, San Francisco Cochrane Center
  • 6/00-present
    Vice Chair, Department of Clinical Pharmacy, UCSF
  • 6/01-present
    Professor, Dept. Clinical Pharmacy/ Institute for Health Policy Studies/ Center for Tobacco Control Research and Education, UCSF

Honors & Awards

  • 1994-1992
    Special Consultant to the European Union Committee on Technology Assessment
  • 1992
    Best article published in 1996 in the Intl J Technology Assessment in Health Care
  • 1992
    Special consultant to the World Bank for a background paper on Tobacco Control Policies
  • 2000-2001, 2002
    Special Advisor to World Health Organization

Selected Publications

  1. Chang L, Dhruva SS, Chu J, Bero LA, Redberg RF. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. BMJ. 2015; 350:h2613.
    View on PubMed
  2. Tran DN, Bero LA. Barriers and facilitators to the quality use of essential medicines for maternal health in low-resource countries: An Ishikawa framework. J Glob Health. 2015 Jun; 5(1):010406.
    View on PubMed
  3. Schroll JB, Bero L. Regulatory agencies hold the key to improving Cochrane reviews of drugs. Cochrane Database Syst Rev. 2015 Apr 20; 4:ED000098.
    View on PubMed
  4. Siler K, Lee K, Bero L. Reply to Margalida and Colomer: Science should strive to prevent mistakes, not corrections. Proc Natl Acad Sci U S A. 2015 Mar 31; 112(13):E1512.
    View on PubMed
  5. Anglemyer AT, Krauth D, Bero L. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis. BMC Med Res Methodol. 2015; 15(1):12.
    View on PubMed
  6. Hill SR, Bero L, McColl G, Roughead E. Expensive medicines: ensuring objective appraisal and equitable access. Bull World Health Organ. 2015 Jan 1; 93(1):4.
    View on PubMed
  7. Siler K, Lee K, Bero L. Measuring the effectiveness of scientific gatekeeping. Proc Natl Acad Sci U S A. 2015 Jan 13; 112(2):360-5.
    View on PubMed
  8. Forsyth SR, Odierna DH, Krauth D, Bero LA. Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles. Syst Rev. 2014; 3(1):122.
    View on PubMed
  9. Bero L. Bias related to funding source in statin trials. BMJ. 2014; 349:g5949.
    View on PubMed
  10. Fox DM, Bero L. Systematic reviews: perhaps "the answer to policy makers' prayers"? Environ Health Perspect. 2014 Oct; 122(10):A262-3.
    View on PubMed
  11. Magrini N, Robertson J, de Joncheere K, Bero L. On WHO's essential medicines process and transparency. BMJ. 2014; 349:g5637.
    View on PubMed
  12. Formoso G, Marata AM, Magrini N, Bero L. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev. 2014; 9:ED000090.
    View on PubMed
  13. Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. J Clin Epidemiol. 2015 Jan; 68(1):102-7.
    View on PubMed
  14. Bero L. What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. J Clin Epidemiol. 2014 Nov; 67(11):1239-41.
    View on PubMed
  15. Mahady SE, Schlub T, Bero L, Moher D, Tovey D, George J, Craig JC. Side effects are incompletely reported among systematic reviews in gastroenterology. J Clin Epidemiol. 2015 Feb; 68(2):144-53.
    View on PubMed
  16. Tovey D, Churchill R, Bero L. Evidence based medicine: looking forward and building on what we have learnt. BMJ. 2014; 349:g4508.
    View on PubMed
  17. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014; 4:MR000034.
    View on PubMed
  18. Coralic Z, Kanzaria HK, Bero L, Stein J. Staff Perceptions of an On-site Clinical Pharmacist Program in an Academic Emergency Department after One Year. West J Emerg Med. 2014 Mar; 15(2):205-10.
    View on PubMed
  19. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria: Krauth et al. Respond. Environ Health Perspect. 2014 Mar; 122(3):A67.
    View on PubMed
  20. Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol. 2014 Jan; 12(1):e1001770.
    View on PubMed

Go to UCSF Profiles, powered by CTSI